MRNS MARINUS PHARMACEUTICALS, INC. revenue, earnings and financials
For the quarter ended September 30, 2024, MARINUS PHARMACEUTICALS, INC. reported revenue of $8.54M (up 16.4% from a year earlier), net income of −$24.2M and diluted EPS of −$0.42; over the last four quarters revenue was $31.5M and net income −$140M; for the fiscal year ended December 2023 revenue was $31.0M, up 21.6% on the year before.
MRNS annual revenue and earnings
- Fiscal year ended Dec 2023: revenue $31.0M, gross profit n/a, operating income −$131M, net income −$141M (margin -456.3%), EPS −$2.63
- Fiscal year ended Dec 2022: revenue $25.5M, gross profit n/a, operating income −$113M, net income −$19.8M (margin -77.8%), EPS −$0.51
- Fiscal year ended Dec 2021: revenue $15.3M, gross profit n/a, operating income −$96.9M, net income −$98.8M (margin -643.7%), EPS −$2.69
MRNS quarterly revenue and earnings
- Quarter ended Sep 30, 2024: revenue $8.54M (up 16.4% year over year), net income −$24.2M, EPS −$0.42
- Quarter ended Jun 30, 2024: revenue $8.06M (up 32.5% year over year), net income −$35.8M, EPS −$0.63
- Quarter ended Mar 31, 2024: revenue $7.68M (down 26.0% year over year), net income −$38.7M, EPS −$0.68
- Quarter ended Dec 31, 2023 (from the annual report): revenue $7.19M (up 0.4% year over year), net income −$41.8M, EPS −$0.74
- Quarter ended Sep 30, 2023: revenue $7.34M (up 213.6% year over year), net income −$33.0M, EPS −$0.61
- Quarter ended Jun 30, 2023: revenue $6.08M (up 239.7% year over year), net income −$31.9M, EPS −$0.61
- Quarter ended Mar 31, 2023: revenue $10.4M (down 26.8% year over year), net income −$34.7M, EPS −$0.67
- Quarter ended Dec 31, 2022 (from the annual report): revenue $7.16M (up 371.2% year over year), net income −$34.3M, EPS −$0.82
- Quarter ended Sep 30, 2022: revenue $2.34M (down 76.9% year over year), net income $73.3M, EPS $1.89
- Quarter ended Jun 30, 2022: revenue $1.79M (down 6.0% year over year), net income −$39.4M, EPS −$1.06
- Quarter ended Mar 31, 2022: revenue $14.2M (up 685.5% year over year), net income −$19.4M, EPS −$0.52
- Quarter ended Dec 31, 2021 (from the annual report): revenue $1.52M, net income −$28.3M, EPS −$0.77
- Quarter ended Sep 30, 2021: revenue $10.1M, net income −$19.5M, EPS −$0.53
- Quarter ended Jun 30, 2021: revenue $1.91M, net income −$23.8M, EPS −$0.65
- Quarter ended Mar 31, 2021: revenue $1.81M, net income −$27.1M, EPS −$0.74
MRNS cash flow, buybacks and dividends
- Fiscal year ended Dec 2023: operating cash flow −$118M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$113M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$55.5M, share buybacks n/a
MRNS balance sheet
- Sep 30, 2024: cash $42.2M, total assets $63.6M, total liabilities $130M, shareholders' equity −$66.7M
- Jun 30, 2024: cash $64.7M, total assets $87.1M, total liabilities $134M, shareholders' equity −$47.3M
- Mar 31, 2024: cash $104M, total assets $137M, total liabilities $154M, shareholders' equity −$16.4M
- Dec 31, 2023: cash $121M, total assets $171M, total liabilities $154M, shareholders' equity $16.8M
- Sep 30, 2023: cash $140M, total assets $201M, total liabilities $146M, shareholders' equity $54.5M
- Jun 30, 2023: cash $128M, total assets $201M, total liabilities $144M, shareholders' equity $57.3M
- Mar 31, 2023: cash $147M, total assets $227M, total liabilities $142M, shareholders' equity $85.1M
- Dec 31, 2022: cash $241M, total assets $260M, total liabilities $144M, shareholders' equity $116M
What is MRNS's revenue?
MARINUS PHARMACEUTICALS, INC. reported $31.5M of revenue over its last four quarters, through September 30, 2024.
Is MRNS profitable?
No. MARINUS PHARMACEUTICALS, INC. lost $140M over the last four quarters.
What is MRNS's EPS?
Diluted earnings per share over the last four quarters were −$2.47; −$0.42 in the latest quarter.